Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Focal high-intensity focussed ultrasound for the treatment of localized prostate cancer

Posted by on Oct 5, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the use of high-intensity focal ultrasound (HIFU) for the treatment of localized prostate cancer. This study found that HIFU is a safe treatment with good oncological results and minimal side-effects.  Some background High-intensity focused ultrasound (HIFU) is a non-invasive technique that uses...

Read More

Searching for patients with prostate cancer to test an experimental treatment before surgery

Posted by on Oct 3, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is investigating the effectiveness of pembrolizumab (Keytruda) plus enzalutamide (Xtandi) in patients with prostate cancer. The primary outcome to be measured will be the absence of cancer on the prostate after it is surgically removed. This study is being conducted in Portland, OR. The details...

Read More

What are the outcomes of sipuleucel-T treatment for patients with metastatic castration-resistant prostate cancer?

Posted by on Oct 1, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects. Some background...

Read More

Searching for patients with advanced prostate cancer to test an experimental medication

Posted by on Sep 30, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of AZD4635 in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The main outcome will be the objective response rate (ORR) and prostate-specific antigen (PSA; a marker of prostate cancer) response. This trial is recruiting in multiple...

Read More

Evaluating the safety of re-treatment with radium-223

Posted by on Sep 16, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results. Some background...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Looking for patients with advanced prostate cancer to test a new treatment

Posted by on Sep 10, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as prostate cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Looking for patients with high-risk prostate cancer to test a combination therapy

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This study aims to examine the effectiveness of niraparib (Zejula) combined with hormone therapy and radiotherapy to treat patients with high-risk prostate cancer. The main outcome to be measured will be how long patients remain cancer-free. This study is recruiting in Philadelphia, PA. The details Prostate cancer occurs mostly...

Read More

Looking for patients with prostate cancer to test a combination of radiotherapy

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic ablative radiation therapy (SABR) and radiopharmaceutical therapy (RPT) in patients with oligometastatic (cancer spread in 1-2 other tissues or organs) prostate cancer. The main outcome will be progression-free survival (PFS). This trial is recruiting in Maryland,...

Read More

Evaluating enzalutamide plus androgen deprivation therapy to treat metastatic prostate cancer

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...

Read More